SNDX-5613
Revumenib (SNDX-5613) is a potent and selective oral inhibitor that disrupts the menin-KMT2A protein interaction with sub-nanomolar affinity. It is utilized in research on acute leukemias harboring MLL rearrangements, showing activity in both cellular assays and in vivo animal models.
Product Specifications
CAS Number
2169919-21-3
Product Name Alternative
Acute, ALL, AML, myeloid, inhibit, Inhibitor, lymphoblastic, MLL, Leukemia, Menin, Menin-MLL, HistoneMethyltransferase, Histone Methyltransferase, Epigenetic Reader Domain, EpigeneticReaderDomain, SNDX 5613, SNDX5613, SNDX-5613
Field of Research
Epigenetics & Chromatin
Purity
98.70% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween-80+45% Saline:4 mg/mL (6.34 mM) ; DMSO:52 mg/mL (82.43 mM)
Smiles
CCN (C (C) C) C (=O) c1cc (F) ccc1Oc1cncnc1N1CC2 (C1) CCN (C[C@H]1CC[C@@H] (CC1) NS (=O) (=O) CC) CC2
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.82
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
